



A Career Planning Tool For Chemical Scientists





ChemIDP is an Individual Development Plan designed specifically for graduate students and postdoctoral scholars in the chemical sciences. Through immersive, self-paced activities, users explore potential careers, determine specific skills needed for success, and develop plans to achieve professional goals. **ChemIDP** tracks user progress and input, providing tips and strategies to complete goals and guide career exploration.

https://chemidp.acs.org



- ACS Member-exclusive program that allows you to arrange a one-on-one appointment with a certified ACS Career Consultant.
- Consultants provide personalized career advice to ACS Members.
- Browse our Career Consultant roster and request your one-on-one appointment today!

www.acs.org/careerconsulting

6



https://www.acs.org/content/acs/en/careers/developing-growing-in-your-career.html

ACS Bridge Program



Are you thinking of Grad School?

If you are a student from a group underrepresented in the chemical sciences, we want to empower you to get your graduate degree!

The ACS Bridge Program offers:

- A FREE common application that will highlight your achievements to participating Bridge Departments
- Resources to help write competitive grad school applications and connect you with mentors, students, and industry partners!

Learn more and apply at <u>www.acs.org/bridge</u> Email us at <u>bridge@acs.org</u>







ACS Scholar Adunoluwa Obisesan

BS, Massachusetts Institute of Technology, June 2021 (Chemical-biological Engineering, Computer Science & Molecular Biology)

"The ACS Scholars Program provided me with monetary support as well as a valuable network of peers and mentors who have transformed my life and will help me in my future endeavors. The program enabled me to achieve more than I could have ever dreamed. Thank you so much!"

GIVE TO THE



Donate today at www.donate.acs.org/scholars





9















































https://www.youtube.com/c/ACSReactions/videos

10

5







zi and K. Ba less chat about shar 2022 Nobel Prize in Chemistry ing



Vade on Wikipedia work-life balance



orthogonal, click chemistry clinch the Nobel Prize er 5. 2022







The sticky science of why eat so much sugar May 31, 2022

Lithium mining's wate sparks bitter conflicts novel chemistry



There's more to James Harris's story April 27, 2022





The helium shortage th wasn't supposed to be March 24, 2022

Subscribe now to C&EN's podcast

STITCHER

VOICES AND STORIES FROM THE WORLD OF CHEMISTRY





ACS Industry Member Programs

ACS Industry Matters

ACS member only content with exclusive insights from industry leaders to help you succeed in your career. #ACSIndustryMatters

Preview Content: acs.org/indnl

ACS Innovation Hub LinkedIn Group

Connect, collaborate and stay informed about the trends leading chemical innovation.

Join: bit.ly/ACSinnovationhub

ACS on Campus is the American Chemical Society's initiative dedicated to helping students advance their education and careers.





15

ACS OFFICE OF DEIR

Advancing ACS' Core Value of Diversity, Equity, Inclusion and Respect

Resources









17



www.acs.org/acswebinars





Wed., March 15, 2023 | 2:00-3:00pm ET

Successful Transitions: Strategies for Adapting to a New Role

Co-produced with the ACS Younger Chemists Committee and the ACS Committee on Ethics

Register for Free



Thurs., March 16, 2023 | 2:00-3:00pm ET

Toxicology 101: Chemicals and their Toxic Effects

Co-produced with the ACS Office of Career and Professional Education



Wed., March 23, 2023 | 1:00-2:00pm ET

How Artificial Intelligence is Changing Drug Discovery

Co-produced with the Science History Institute

Browse the Upcoming Schedule at www.acs.org/acswebinars







CAS connect you to the world's published science for better insights



Over **50K** scientific journals and documents

Over **50** languages translated Over **250** million substances

Over 64 patent offices worldwide



21 © 2023 American Chemical Society. All rights reserved

21

Data is valuable only when it is transformed into insight





What are exosomes?

Function and Characterization





Why exosomes?

Synthetic



Low bioavailability | Rapid bloodstream clearance | Cytotoxicity

25 © 2023 American Chemical Society. All rights reserved.

Natural



Innate stability | Biocompatibility | Low immunogenicity | Crosses blood-brain barrier



Exosome publications has increased over time

Research in exosomes is outpacing LNP







Cancer leads the way

amongst a wide range of diseases



27 © 2023 American Chemical Society. All rights reserved.

CAS CAS

27

There's a challenge: isolating and purifying exosomes





With a wide range of approaches...





Ultracentrifugation Density and size based sequential separations



Ultrafiltration Filter membrane with defined size-exclusion limit purity, integrity



Polymer precipitation Polymer adhering and precipitating exosomes purity, speed

Size exclusion chromatography

Hydrodynamic radii exosome separation



X throughput, automation



29

Immunoaffinity Antigen–antibody specific recognition and binding X yield, speed





Microfluidics Immunoaffinity, size, density

X throughput, scale, speed



Exosome application publications







Exosomes in the clinical development pipeline

Preclinical Development and Clinical Trials



Exosomes in clinical trials	Therapeutic Focus
bmMSC-derived exosomes	ARDS, IBD
bmMSC-derived exosomes	Wound healing
amniotic fluid derived exosomes	ARDS
Purified exosome product	Wound healing/ Myocardial infarction
exosome with ASO-STAT6	Hepatocellular Carcinoma
umbilical cord derived exosomes	ARDS
ginger exosomes	IBD
MSCs-derived exosome with KrasG12D siRNA	Pancreatic cancer



31

Exosome research activity Companies and their targeted diseases





Clinical Application of Exosome Based Therapy

Atta Behfar, M.D., Ph.D.

Russ and Kathy Van Cleve Professor of Regenerative Medicine, Consultant, Interventional Cardiology, Heart Transplant Director, Van Cleve Cardiac Regenerative Medicine Program Co-Director of Innovation in Biologics, Cardiology Research Program Director, Cardiology Fellowship Program Professor, Mayo College of Medicine

Disclosures for Atta Behfar, M.D., Ph.D.

- Relevant Financial Relationships
 - Rion Inc
 - Sorento Therapeutics
 - Deverra Therapeutics
- Off label usage TISSEEL
- Additional Disclosures
 - Abbott Steering Committee



Learning Objectives

- Evolution of stem cells to exosomes
- Describe the use of naturally occurring extracellular vesicles for therapeutic applications
- Summarize how to engineer extracellular vesicles for therapeutic delivery in wound and cardiovascular space







GD.

Engineering exosomes therapies



Master Cell Banks



Bioreactor Purification

Cells engineered with unique membrane proteins designed for endosomal trafficking

cDNA, mRNA and miRNA/siRNA targeting

Proteins and growth factor overexpression or targeting

Massive cell expansion

Conditioned medium harvest

Size/affinity-based purification



37

CLINICAL EXPERIENCE

TRIAL RESULTS IDENTIFY A HIGHLY REGENERATIVE CELL



2			

CLINOMICS- CHART-1/C-CURE TRIAL DATA hrCP more efficient at exosome release



39

CLINOMICS- CHART-1/C-CURE TRIAL DATA

miRNA/Secretome Interactome Profiling of CP versus hrCP Exosomes



Manufacturing Maintains Exosome Structure/Function

Conventional manufacturing process often destroys exosomes



RION

41

Regenerative Exosomes: How They Work

MODE OF ACTION Reduces oxidative stress helping cells survive

- · Reduces inflammation to allow for healing
- · Activates stem cells to help with tissue repair
- · Restores healthy blood supply

Pre-clinical data demonstrates that PEP capable of regenerating many types of tissue: skin, heart, muscle, tendon, lung and nerve



PEP stimulate the body's natural tissue regenerative process

Compassionate Use – Radiation injury in the setting of skin cancer

• Dr. Katie Van Able

- ENT / Department of Head and Neck Surgery at Mayo Clinic
- >1yr non-healing wound
- Second round of therapy planned

Platelet Derived Exosomes

- <u>P1 Clinical Study on ischemic wound healing</u> <u>completed at Mayo Clinic</u>
- P2 Multi-center study on ischemic wound in 2023
- Compassionate use
 - Radiation
 - Non-healing wounds
 - DOD applications

MAYO

43





©2017 MFMER | slide-43





Anti-oxidant enzymes protect cells from oxidative stress

45

Restoration of Microvascular Content





Modulation of inflammation through macrophage polarization

In vivo application of PEP in acute myocardial infarction





Cardiac Regeneration (EV AMI Trial)

EV AMI TRIAL





WAYO CLINIC

Van Cleve Cardiac Regenerative Medicine Program

DISCOVERY

Paul Stalboerger Tim Peterson Matt Hillestad Zeji Du Amanda Terlap Skylar Rizzo Monique Bagwell Matt Hillestad Mohsin Abbas Humberto DeVitto Parisa Kargaran

PRE-CLINICAL

Tyra Witt Mary Nagel Tiffany Griffiths HISTOLOGY Ryan Mahlberg

CLINIC CLINIC

51

OMICS Kent Arrell

NANO SCIENCE Carmen Terzic Sungjo Park

CLINICAL Drew Rosen

Drew Rosenbaum, MD Michael Sabbah, MD Suraj Yalamuri, MD

Scientific Advisors Andre Terzic Scott Kaufmann

Clinical Collaborators

Steve Moran Emanuel Trabuco Rafael Sierra Matt Houdek Peter Amadio Chunfeng Zhao Andrea Boon Saranya Wyles John Occhino Zaraq Khan

Former Members Ramandeep Takhter Christopher Livia Cody Wyles Kevini Ao Shi Mark Li Tyler Rolland Dhyvia Meenakshi Ruben Crespo-Diaz Elli Jacobson Matt Amontree

©2017 MFMER | slide-51



۲

Timothy Moseley, PhD

Chief Technology Officer / Owner

Direct Biologics, LLC HQ: Austin, Texas





Direct Biologics is a Late-stage biotechnology company focused on directing the next paradigm shift in medicine with its platform of therapeutics called extracellular vesicles





ExoFlo[®]

- ExoFlo is a natural extracellular vesicle product isolated from human bone marrow MSCs that contains growth factors and extracellular vesicles including exosomes.
- Extracellular vesicles are 30-150 nm in size and are involved in direct cell to cell communication.
- The extracellular vesicles are manufactured and purified using proprietary cGMP processing and are sterile per USP<71>.





Mesenchymal Stem Cell EV and Exosome Signals

- Chemotaxis & Migration (e.g., MCSF, PDGF, SDF-1...)
- Angiogenesis (e.g., Angiogenin, PIGF, VEGF...)
- Extracellular Matrix Development & Repair (e.g., ICAMs, TIMPs...)
- Inflammation & Cell Survival Support (e.g., TGFβs, MIF, Interleukins...)

©2023 Direct Biologics, LLC – All rights reserved

- Tissue & Wound Repair (e.g., bFGF, Activin, HGF...)
- Tumor Suppressor (e.g., DAN, OPN, IGFBPs..)



3/9/2023

Direct Biologics EV Drug Pipeline					
Therapeutic Area	Preclinical Studies	nical IND-enabling ies Clinical Studies Phase I Phase II		Phase II	Phase III
COVID-19 ARDS (Moderate to Severe) RMAT Designation	Completed	Completed	Completed	Completed	In Progress
	Completed	Completed	Open-Label Expanded Access - Granted		
	Completed	Completed	eIND - Emergency Approval for Single Patient		ngle Patients
Post-Acute COVID	Completed	Completed	In Progress	TBD	TBD
Mild-Moderate COVID	Completed	Completed In Progress		TBD	TBD
ARDS (non-COVID-19)	Completed	Completed	In Progress		TBD
UC / Crohn's	Completed	Completed	In Progress		TBD
Organ Transplant GvHD	Completed	Completed	In Progress		TBD
Osteoarthritis	Completed	Completed	TBD TBD		TBD

57

COVID-19 & Acute Respiratory Distress Syndrome



SARS-CoV-2 infects via binding to ACE2 receptors, causing tissue damage and release of inflammatory cytokines by epithelial cells and immune cells.

Then, the crosstalk between epithelial cells and immune cells leads to a wide range of clinical manifestations:

- Mild forms (e.g., fever, cough, and myalgia)
- Moderate forms requiring hospitalization (pneumonia and localized inflammation)
- Severe/Critical forms with often fatal outcomes that are manifested as pneumonia, ARDS, DIC, and multiorgan failure.

ARDS usually leads to formation of gel in the lungs and patients require mechanical ventilation that has an approximate 50% mortality rate.

Yang L, Xie X, Tu Z, et al. The signal pathways and treatment of cytokine storm in COVID-19, Nature-Signal Transduction and Targeted Therapy (2021) 6:255

ExoFlo[™] to Treat Severe ARDS from COVID-19



Investigator Initiated Trial (April 2020):

N=24 Severe ARDS patients with COVID-19 treated with 15mL ExoFlo under hospital IRB and physician oversight

Acute phase reactants (CRP, ferritin, & D-dimer) Before Treatment vs. 5 days post ExoFlo

- C-Reactive Protein (CRP) = 77% reduction (p<0.001)</p>
- Ferritin = 43% reduction (p<0.001)
- D-Dimer = **42%** reduction (p<0.05)
- Absolute Neutrophil Count (ANP) = 32% reduction (p<0.001)

Immune cell populations

- Total Lymphocyte Count = 36% increase (P < 0.05)
- CD3+ T Lymphocytes = 46% increase (p<0.05)
- CD4+ T Lymphocytes = 45% increase (p<0.05)
- CD8+ T Lymphocytes = 46% increase (p<0.001)

Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells & Dev. 2020;29(12):747-754. doi:10.1089/scd.2020.0080

59



Phase II (Dosing Study) - Completed

- Prospective, Double-Blind, Placebo Controlled, Randomized, Multi-Center Study
- 10mL or 15mL on Day 1 and Day 4 (Phase I was single 15mL Tx)
- Primary outcome 60-day mortality
- Completed successfully
- Submitted for publication (expect to be In-Press soon)

Expanded Access (Safety & Efficacy Study) - Completed

- Prospective, Open-label Trial, multi-center
- 50 patients per center

Phase III (Efficacy Study)

Prospective, Double-Blind, Placebo Controlled, Randomized, Multi-Center Study

©2023 Direct Biologics, LLC - All rights reserved

Currently enrolling patients



IIT/IRB Clinical Study – Osteoarthritis Pain

A Study to Evaluate the Safety of a Bone Marrow Derived Mesenchymal Stem Cell Extracellular Vesicle Isolate Product for the Treatment of Osteoarthritis in Combat Injured Joints

- Retired US Navy SEALS with joint pain (n=33)
- Prospective, Open Label, Non-Randomized
- Treat Grade 2-4 Kellgren-Lawrence OA Joints
- 2mL EVs per painful joint (n=132 joints)
- Primary Outcome = Safety Completed! Zero Adverse Events Safety
- Secondary Outcome = Detailed joint specific pain questionnaires: Pre-injection (baseline); 6 weeks; 3 mo; 6 mo; 12 mo

61

IIT/IRB Clinical Study – Osteoarthritis Pain

Patient Progress vs. Time after ExoFlo injection into Joints (n=132)



p < 0.001 for all timepoints versus pre-treatment baseline.

East, J., and Dordevic, M., Journal of Stem Cell Research 2021;2(2)-21.



ARUNABIO

Blood brain Barrier: Exosome Capabilities and Opportunities

Dr. Steve Stice Chief Scientific Officer Professor, University of Georgia

March 9th, 2023



65

Proprietary In-house Manufacturing and Production



ARUNABIO

65

AB126: Specialized Exosome from Proprietary Neural Stem Cell Line

AB126 is an unmodified exosome derived from neural stem cells with ability to cross the BBB and contain therapeutic activity in its native form



ARUNABIO

Exosomes Regardless of Species and Type Cross BBB



Confirming AB126 Distribution in the Disrupted and Inflamed Brain

- · Accomplished by labelling AB126 with indium-111 vs free I-111
- Mice were injected 1 hr. post stroke and imaged 1 hr. after injection by single photon emission computed tomography (SPECT)
- AB126 was present in the infarcted hemisphere and preferentially accumulates in the penumbra of the injury



ARUNABIO . Translational Stroke Research (2018) 9:530-539

69

Preclinical Data – AB126 Has High BBB Permeability



AB126 Demonstrates Greater Brain Uptake, Distribution and Durability vs. Non-Neural Exosomes

ARUNABIO

*HEK293 is a widely available commercial cell line

69

Strategies for Enhancing Exosome Brain Delivery



- RVG-exosome; Lamp2ba liganddecorating combined with rabies virus glycoprotein (RVG), a small peptide that specifically binds to an acetylcholine receptor expressed by neuronal cells.
- TfR1 presence in some not all EVs, can they be further enhanced
- Kim et al. used a T7 peptide, a TfRbinding peptide, for the delivery of exosomes (. J. Control. Release 2020, 317, 273–281)

Choi et al., (review) 2023 Pharmaceutics

AB126 Facilitates Tissue Repair Post Ischemic Stroke

Proprietary Porcine Stroke Model (West Lab)

- · Ischemic stroke results in massive neuronal cell death, leading to severe neurological damage
- · AB126 preserved cells, evident after only 24 hours, and continues to prevent tissue damage 3 months post-dosing



ARUNABIO

Source: Webb, et al. Human Neural Stem Cell Extracellular Vesicles Improve Recovery in a Porcine Model of Ischemic Stroke. Stroke, 2018.

71

AB126 Decreases Lesion Size: neurogenic and vasculogenic



ARUNABIO + neurons (NeuN; green), reactive astrocytes (glial fibrillary acidic protein; red), macrophages and microglia (CD68; magenta) and 4;6-diamidino-2-phenylindole counterstain (blue)

AB126 Can Carry Large Quantities of Payloads



AB126 Transports Fluorescent Tagged siRNA Payload into Neural Cell Line (N2a)

AB126 alone AB126 + siRNA

N2a are a neural cell line

Visible and measurable high levels of fluorescent (pink/purple) tagged siRNA cargo in AB126 (lower right)

ARUNABIO

AB126 Facilitates Delivery of siRNA to the Rodent Brain

- Healthy mice were dosed <u>systemically</u> with matching amounts of cholesterol siRNA or AB126 + cholesterol siRNA
- 72 hours post-administration, perfused brain dissected and assayed for siRNA via qPCR
- AB126 delivers 2.1x (cerebellum), 3.4x (cortex) and 3.5x (striatum) more siRNA to the mouse brain compared to siRNA alone



ARUNABIO



CONTACT:

Steve Stice sstice@arunabio.com

ARUNABIO

LEADER IN THE DEVELOPMENT OF NEURAL EXOSOMES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES





Gain insight at the intersection of science, tech and innovation

Connect with us at cas.org/insights					
🖽 Insight Re	eports 🔟 Article	es 📕 Journal P	ublications	4	
Topics: Drug Discovery Sustainability	Emerging Science Intellectual Property	Consumer Goods Synthetic Chemistry	Digital R&D Biotechnology	Safety Materi	



CS Webinars

79



www.acs.org/acswebinars



Wed., March 15, 2023 | 2:00-3:00pm ET

Successful Transitions: Strategies for Adapting to a New Role

Co-produced with the ACS Younger Chemists Committee and the ACS Committee on Ethics

Register for Free



Thurs., March 16, 2023 | 2:00-3:00pm ET

Toxicology 101: Chemicals and their Toxic Effects

Co-produced with the ACS Office of Career and Professional Education



Wed., March 23, 2023 | 1:00-2:00pm ET

How Artificial Intelligence is Changing Drug Discovery

Co-produced with the Science History Institute

Browse the Upcoming Schedule at www.acs.org/acswebinars



www.acs.org/acswebinars



Learn from the best and brightest minds in chemistry!

Hundreds of webinars on a wide range of topics relevant to chemistry professionals at all stages of their careers, presented by top experts in the chemical sciences and enterprise.



LIVE

Edited Recordings

are an exclusive benefit for ACS Members with the Premium Package and can be accessed in the ACS Webinars[®] Library at <u>www.acs.org/acswebinars</u>

Live Broadcasts

of ACS Webinars[®] continue to be available free to the general public several times a week generally from 2-3pm ET. Visit <u>www.acs.org/acswebinars</u> to register* for upcoming webinars.

*Requires FREE ACS ID

81





ACS Webinars[®] does not endorse any products or services. The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the American Chemical Society.

Contact ACS Webinars® at acswebinars@acs.org

